Cancer

Title
Study of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer
Trial Number
204224032112
Number of Participants
1,500
Principal Investigator

Ellen R. Gaynor

M.D.
Hematology/Oncology
Professor
Eligibility

Men at least 18 years of age that have advanced prostate cancer that is being treated with sipuleucel-T will be eligible.

Purpose

The purpose of this study is to learn more about the occurrence of cerebrovascular events (more commonly known as “strokes”) reported during or following sipuleucel-T therapy, and about the survival of all study subjects.

Enrollment

(708) 327-3101

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.